Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort

References

• http://globocan.iarc.fr.
   Google Scholar
• Blanchard P, Lee AWM, Carmel A, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2022;32:59–68.
   PubMed Web of Science ®Google Scholar
• Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403.
   PubMed Web of Science ®Google Scholar
• Mao YP, Tang LL, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chinese J Cancer. 2016;35:103.
   PubMedGoogle Scholar
• Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317.
   PubMed Web of Science ®Google Scholar
• Pfister DG, Spencer S, Brizel DM, et al. Head and neck cancers, version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12(10):1454–1487.
   PubMedGoogle Scholar
• Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomized controlled trial. Lancet Oncol. 2012;13(2):163–171.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial. Lancet Oncol. 2016;17(11):1509–1520.
   PubMed Web of Science ®Google Scholar
• International Nasopharynx Cancer Study Group; VUMCA I Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996;35(3):463–469.
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998;83(11):2270–2283.
   PubMed Web of Science ®Google Scholar
• Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19(5):1350–1357.
   PubMed Web of Science ®Google Scholar
• Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002;20(7):1845–1852.
   PubMed Web of Science ®Google Scholar
• Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC early clinical trials group. Ann Oncol. 1994;5(6):533–537.
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14(5):1672–1678.
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern cooperative oncology group trial (PA390). Cancer. 1998;82(11):2270–2274.
   PubMed Web of Science ®Google Scholar
• Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–249.
   PubMed Web of Science ®Google Scholar
• Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21(4):631–637.
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20(8):2038–2044.
   PubMed Web of Science ®Google Scholar
• Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–736.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomized, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–1892.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–1135.
   PubMed Web of Science ®Google Scholar
• OuYang PY, Xie C, Mao YP, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013;24(8):2136–2146.
   PubMed Web of Science ®Google Scholar
• Chen YP, Guo R, Liu N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a bayesian network meta-analysis of randomized controlled trials. J Cancer. 2015;6(9):883–892.
   PubMed Web of Science ®Google Scholar
• Song Y, Wang W, Tao G, et al. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma–a time-to-event meta-analysis. Oral Oncol. 2015;51(8):764–769.
   PubMed Web of Science ®Google Scholar
• Yan M, Kumachev A, Siu LL, et al. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a bayesian network meta-analysis. Eur J Cancer. 2015;51(12):1570–1579.
   PubMed Web of Science ®Google Scholar
• Wang M, Tian H, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(30):48375–48390.
   PubMedGoogle Scholar
• He J, Wu P, Tang Y, et al. Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis. Oncotarget. 2017;8(24):39782–39794.
   PubMedGoogle Scholar
• Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24(8):1824–1833.
   PubMed Web of Science ®Google Scholar
• Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis. Radiother Oncol. 2018;129(1):10–17.
   PubMed Web of Science ®Google Scholar
• Zhang B, Li MM, Chen WH, et al. Association of chemoradiotherapy regimens and survival among patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1913619.
   PubMed Web of Science ®Google Scholar
• Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomized controlled trial. Eur J Cancer. 2017;75:14–23.
   PubMed Web of Science ®Google Scholar
• Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87–96.
   PubMed Web of Science ®Google Scholar
• Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (mach-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group. Radiother Oncol. 2021;156:281–293.
   PubMed Web of Science ®Google Scholar
• Noronha V, Joshi A, Patil VM, et al. Once-a-Week versus Once-Every-3-Weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018;36(11):1064–1072.
   PubMed Web of Science ®Google Scholar
• Kiyota N, Tahara M, Mizusawa J, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol. 2022;40(18):1980–1990.
   PubMed Web of Science ®Google Scholar
• Jagdis A, Laskin J, Hao D, et al. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC). Am J Clin Oncol. 2014;37(1):63–69.
   PubMed Web of Science ®Google Scholar
• Tao CJ, Lin L, Zhou GQ, et al. Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma. PLoS One. 2014;9(10):e110765.
   PubMed Web of Science ®Google Scholar
• Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Oncotarget. 2015;6(35):38381–38397.
   PubMedGoogle Scholar
• Peng H, Chen L, Li WF, et al. The cumulative cisplatin dose affects the Long-Term survival outcomes of patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Sci Rep. 2016;6:24332.
   PubMed Web of Science ®Google Scholar
• Meng DF, Sun R, Peng LX, et al. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer. 2018;9(1):92–99.
   PubMed Web of Science ®Google Scholar
• Wen DW, Li ZX, Chen FP, et al. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy. Oral Oncol. 2020;107:104675.
   PubMed Web of Science ®Google Scholar
• Peng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective phase III clinical trial. Oncologist. 2016;21(11):1369–1376.
   PubMed Web of Science ®Google Scholar
• Lee AW, Tung SY, Ngan RK, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011;47(5):656–666.
   PubMed Web of Science ®Google Scholar
• Lv JW, Qi ZY, Zhou GQ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109(3):751–763.
   PubMed Web of Science ®Google Scholar
• Xu Z, Yang L, Ng WT, et al. A Single-Arm phase 2 trial on induction chemotherapy followed by concurrent chemoradiation in nasopharyngeal carcinoma using a reduced cumulative dose of cisplatin. Front Oncol. 2022;12:842281. PMID: 35574402; PMCID: PMC9092977.
   PubMed Web of Science ®Google Scholar
• Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for Definitive-Intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39(7):840–859.
   PubMed Web of Science ®Google Scholar
• Zong YS, Zhang RF, He SY, et al. Histopathologic types and incidence of malignant nasopharyngeal tumors in zhongshan county. Chin Med J (Engl). 1983;96(7):511–516.
   PubMed Web of Science ®Google Scholar
• Han JE, Yi SK, Wang S, et al. Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease. Head Neck. 2019;41(12):4076–4087.
   PubMed Web of Science ®Google Scholar
• Siti-Azrin AH, Norsa’adah B, Naing NN. Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study. BMC Res Notes. 2017;10(1):705.
   PubMedGoogle Scholar
• Tsou YA, Hua CH, Tseng HC, et al. Survival study and treatment strategy for second primary malignancies in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Acta Otolaryngol. 2007;127(6):651–657.
   PubMed Web of Science ®Google Scholar
• Chen MC, Feng IJ, Lu CH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003). Ann Oncol. 2008;19(6):1180–1186.
   PubMed Web of Science ®Google Scholar
• Scélo G, Boffetta P, Corbex M, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. Cancer Causes Control. 2007;18(3):269–278.
   PubMed Web of Science ®Google Scholar
• Goggins WB, Yu IT, Tse LA, et al. Risk of second primary malignancies following nasopharyngeal carcinoma in Hong Kong. Cancer Causes Control. 2010;21(9):1461–1466.
   PubMed Web of Science ®Google Scholar